Literature DB >> 18692657

Preoperative B-type natriuretic peptide is as independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting.

Amanda A Fox1, Stanton K Shernan, Charles D Collard, Kuang-Yu Liu, Sary F Aranki, Stacia M DeSantis, Petr Jarolim, Simon C Body.   

Abstract

OBJECTIVE: Elevated B-type natriuretic peptide is associated with increased morbidity and mortality in ambulatory patients with congestive heart failure or acute coronary syndromes. Its utility in predicting adverse cardiac surgical outcomes is less certain. We hypothesized that preoperative plasma B-type natriuretic peptide would independently predict in-hospital postoperative ventricular dysfunction, hospital stay, and up to 5-year mortality after primary coronary artery bypass grafting.
METHODS: This is a prospective, longitudinal study of 1023 patients at two institutions undergoing primary coronary artery bypass grafting with cardiopulmonary bypass. Ventricular dysfunction was defined as requirement for at least two inotropes or new intra-aortic balloon pump or ventricular assist device support after coronary artery bypass grafting. Multivariable analyses assessed independent roles of preoperative B-type natriuretic peptide in predicting postoperative ventricular dysfunction, hospital stay, and 5-year all-cause mortality.
RESULTS: Preoperative plasma B-type natriuretic peptide concentration predicted ventricular dysfunction, hospital stay, and mortality in univariate and multivariable analyses. Logistic regression demonstrated preoperative B-type natriuretic peptide to independently predict ventricular dysfunction (odds ratio 1.92, 95% confidence interval 1.12-3.29, P = .018), after adjustment for preoperative left ventricular ejection fraction, congestive heart failure severity, and other clinical predictors. Multivariable Cox proportional hazards models showed preoperative B-type natriuretic peptide to independently predict hospital stay (hazard ratio 1.42, 95% confidence interval 1.18-1.72, P = .0002) and mortality (hazard ratio 1.89, 95% confidence interval 1.08-3.33, P = .026).
CONCLUSION: Preoperative plasma B-type natriuretic peptide independently predicted in-hospital ventricular dysfunction, hospital stay, and up to 5-year all-cause mortality after primary coronary artery bypass grafting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18692657      PMCID: PMC2739747          DOI: 10.1016/j.jtcvs.2007.12.036

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  31 in total

1.  B-type natriuretic peptide -- a window to the heart.

Authors:  Kenneth L Baughman
Journal:  N Engl J Med       Date:  2002-07-18       Impact factor: 91.245

2.  N-terminal pro-brain natriuretic peptide identifies patients at high risk for adverse cardiac outcome after vascular surgery.

Authors:  Elisabeth Mahla; Anneliese Baumann; Peter Rehak; Norbert Watzinger; Martin N Vicenzi; Robert Maier; Kurt Tiesenhausen; Helfried Metzler; Wolfgang Toller
Journal:  Anesthesiology       Date:  2007-06       Impact factor: 7.892

3.  B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea.

Authors:  Alex Harrison; L Katherine Morrison; Padma Krishnaswamy; Radmila Kazanegra; Paul Clopton; Quyen Dao; Patricia Hlavin; Alan S Maisel
Journal:  Ann Emerg Med       Date:  2002-02       Impact factor: 5.721

4.  Performance of three preoperative risk indices; CABDEAL, EuroSCORE and Cleveland models in a prospective coronary bypass database.

Authors:  Tuula S Kurki; Otso Järvinen; Matti J Kataja; Jari Laurikka; Matti Tarkka
Journal:  Eur J Cardiothorac Surg       Date:  2002-03       Impact factor: 4.191

5.  Plasma levels of atrial and brain natriuretic peptides as indicators of recovery of left ventricular systolic function after coronary artery bypass.

Authors:  M Chello; P Mastroroberto; F Perticone; F Cirillo; E Bevacqua; S Olivito; E Covino
Journal:  Eur J Cardiothorac Surg       Date:  2001-07       Impact factor: 4.191

6.  Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide.

Authors:  Marc S Sabatine; David A Morrow; James A de Lemos; C Michael Gibson; Sabina A Murphy; Nader Rifai; Carolyn McCabe; Elliott M Antman; Christopher P Cannon; Eugene Braunwald
Journal:  Circulation       Date:  2002-04-16       Impact factor: 29.690

7.  High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure.

Authors:  K Maeda; T Tsutamoto; A Wada; N Mabuchi; M Hayashi; T Tsutsui; M Ohnishi; M Sawaki; M Fujii; T Matsumoto; M Kinoshita
Journal:  J Am Coll Cardiol       Date:  2000-11-01       Impact factor: 24.094

8.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.

Authors:  J A de Lemos; D A Morrow; J H Bentley; T Omland; M S Sabatine; C H McCabe; C Hall; C P Cannon; E Braunwald
Journal:  N Engl J Med       Date:  2001-10-04       Impact factor: 91.245

9.  Plasma brain natriuretic peptide concentration: impact of age and gender.

Authors:  Margaret M Redfield; Richard J Rodeheffer; Steven J Jacobsen; Douglas W Mahoney; Kent R Bailey; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2002-09-04       Impact factor: 24.094

10.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.

Authors:  Patrick Jourdain; Guillaume Jondeau; François Funck; Pascal Gueffet; Alain Le Helloco; Erwan Donal; Jean F Aupetit; Marie C Aumont; Michel Galinier; Jean C Eicher; Alain Cohen-Solal; Yves Juillière
Journal:  J Am Coll Cardiol       Date:  2007-04-02       Impact factor: 24.094

View more
  21 in total

1.  Heart-type fatty acid binding protein is an independent predictor of death and ventricular dysfunction after coronary artery bypass graft surgery.

Authors:  Jochen D Muehlschlegel; Tjörvi E Perry; Kuang-Yu Liu; Amanda A Fox; Charles D Collard; Stanton K Shernan; Simon C Body
Journal:  Anesth Analg       Date:  2010-05-10       Impact factor: 5.108

2.  Assessment of preoperative B-type natriuretic peptide in adult surgeries: is it useful?

Authors:  Amanda A Fox; Simon C Body
Journal:  Anesth Analg       Date:  2011-05       Impact factor: 5.108

3.  Plasma corin decreases after coronary artery bypass graft surgery and is associated with postoperative heart failure: a pilot study.

Authors:  Caryn S Barnet; Xiaoxia Liu; Simon C Body; Charles D Collard; Stanton K Shernan; Jochen D Muehlschlegel; Petr Jarolim; Amanda A Fox
Journal:  J Cardiothorac Vasc Anesth       Date:  2014-11-11       Impact factor: 2.628

4.  B-type natriuretic peptide as a biochemical marker of left ventricular diastolic function: assessment in asymptomatic patients 1 year after valve replacement for aortic stenosis.

Authors:  Vito Mannacio; Anita Antignano; Vincenzo De Amicis; Luigi Di Tommaso; Raffaele Giordano; Gabriele Iannelli; Carlo Vosa
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-05-08

5.  Comparison of the utility of preoperative versus postoperative B-type natriuretic peptide for predicting hospital length of stay and mortality after primary coronary artery bypass grafting.

Authors:  Amanda A Fox; Jochen D Muehlschlegel; Simon C Body; Stanton K Shernan; Kuang-Yu Liu; Tjorvi E Perry; Sary F Aranki; E Francis Cook; Edward R Marcantonio; Charles D Collard
Journal:  Anesthesiology       Date:  2010-04       Impact factor: 7.892

6.  Preoperative brain natriuretic peptide (BNP) is a better predictor of adverse cardiac events compared to preoperative scoring system in patients who underwent abdominal surgery.

Authors:  Paolo Mercantini; Salvatore Di Somma; Laura Magrini; Andrea Kazemi Nava; Andrea Scarinci; Marco La Torre; Mario Ferri; Enrico Ferri; Niccolò Petrucciani; Vincenzo Ziparo
Journal:  World J Surg       Date:  2012-01       Impact factor: 3.352

7.  Does B-type natriuretic peptide or its gene polymorphism predict patient outcome after coronary artery bypass graft surgery?

Authors:  Hai Yu; Da Zhu; Bin Liu
Journal:  Anesthesiology       Date:  2009-12       Impact factor: 7.892

8.  Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting.

Authors:  Amanda A Fox; Charles D Collard; Stanton K Shernan; Christine E Seidman; Jonathan G Seidman; Kuang-Yu Liu; Jochen D Muehlschlegel; Tjorvi E Perry; Sary F Aranki; Christoph Lange; Daniel S Herman; Thomas Meitinger; Peter Lichtner; Simon C Body
Journal:  Anesthesiology       Date:  2009-04       Impact factor: 7.892

9.  Increased perioperative b-type natriuretic peptide associates with heart failure hospitalization or heart failure death after coronary artery bypass graft surgery.

Authors:  Amanda A Fox; Luigino Nascimben; Simon C Body; Charles D Collard; Aya A Mitani; Kuang-Yu Liu; Jochen D Muehlschlegel; Stanton K Shernan; Edward R Marcantonio
Journal:  Anesthesiology       Date:  2013-08       Impact factor: 7.892

Review 10.  Complement activation and cardiac surgery: a novel target for improving outcomes.

Authors:  Gregory L Stahl; Stanton K Shernan; Peter K Smith; Jerrold H Levy
Journal:  Anesth Analg       Date:  2012-07-13       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.